Six refractory lupus patients treated with rituximab: a case series.
Gillis
Joann Zell
JZ
Division of Rheumatology, University of California, San Francisco, CA 94143, USA.
Dall'era
Maria
M
Gross
Andrew
A
Yazdany
Jinoos
J
Davis
John
J
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D007668:Kidney / Q000503:physiopathology; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D019233:Retreatment; D000069283:Rituximab; D012720:Severity of Illness Index
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D005938:Glucocorticoids; D007155:Immunologic Factors; D000069283:Rituximab; D011241:Prednisone